• Bone Biologics posted a net loss of USD 765,988 for the quarter ended March 31, 2026, narrowing 24.69% from a year earlier.
• Operating loss improved 22.48% to USD 805,054 as total operating expenses fell 22.48% to USD 805,054.
• Research and development expense dropped 66.57% to USD 141,597, while general and administrative costs rose 7.89% to USD 663,457.
• Cash totaled USD 4.53 million at March 31, 2026; operating cash outflow was USD 804,282, with available cash expected to fund operations into the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023163), on May 14, 2026, and is solely responsible for the information contained therein.